JP2022533260A - タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 - Google Patents

タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 Download PDF

Info

Publication number
JP2022533260A
JP2022533260A JP2021569449A JP2021569449A JP2022533260A JP 2022533260 A JP2022533260 A JP 2022533260A JP 2021569449 A JP2021569449 A JP 2021569449A JP 2021569449 A JP2021569449 A JP 2021569449A JP 2022533260 A JP2022533260 A JP 2022533260A
Authority
JP
Japan
Prior art keywords
methyl
dioxopiperidine
oxo
optionally substituted
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533260A5 (cg-RX-API-DMAC10.html
Inventor
ダブリュー．エイチ．チャン カイル
イー．アードマン ポール
ファング リーフ
アーロン ヘチト デビット
ホスコテ チョウラシア アパラジタ
ラム イメルダ
メルクウリオ フランク
サリバン ロバート
トーレス エデュアルド
Original Assignee
バイオセリックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオセリックス， インコーポレイテッド filed Critical バイオセリックス， インコーポレイテッド
Publication of JP2022533260A publication Critical patent/JP2022533260A/ja
Publication of JP2022533260A5 publication Critical patent/JP2022533260A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021569449A 2019-05-24 2020-05-22 タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 Pending JP2022533260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852844P 2019-05-24 2019-05-24
US62/852,844 2019-05-24
PCT/US2020/034264 WO2020242960A1 (en) 2019-05-24 2020-05-22 Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications

Publications (2)

Publication Number Publication Date
JP2022533260A true JP2022533260A (ja) 2022-07-21
JP2022533260A5 JP2022533260A5 (cg-RX-API-DMAC10.html) 2023-06-07

Family

ID=71092611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569449A Pending JP2022533260A (ja) 2019-05-24 2020-05-22 タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用

Country Status (14)

Country Link
US (2) US11345712B2 (cg-RX-API-DMAC10.html)
EP (1) EP3976623A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022533260A (cg-RX-API-DMAC10.html)
KR (1) KR20220023343A (cg-RX-API-DMAC10.html)
CN (1) CN114502543A (cg-RX-API-DMAC10.html)
AU (1) AU2020283744A1 (cg-RX-API-DMAC10.html)
CA (1) CA3140078C (cg-RX-API-DMAC10.html)
EA (1) EA202192910A1 (cg-RX-API-DMAC10.html)
IL (1) IL288204A (cg-RX-API-DMAC10.html)
MX (1) MX2021014345A (cg-RX-API-DMAC10.html)
SG (1) SG11202112355VA (cg-RX-API-DMAC10.html)
TW (1) TW202110818A (cg-RX-API-DMAC10.html)
WO (1) WO2020242960A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202109124B (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
IL293481A (en) * 2019-12-06 2022-08-01 Celgene Corp Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
AU2020398965A1 (en) * 2019-12-12 2022-06-30 Biotheryx, Inc. PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications
JP7871189B2 (ja) * 2019-12-17 2026-06-08 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質の動員および／または分解を調節する化合物
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN122562781A (zh) * 2020-10-07 2026-08-14 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
EP4320125A1 (en) * 2021-04-05 2024-02-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
AU2022289605B2 (en) * 2021-06-08 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN117440948A (zh) * 2021-06-28 2024-01-23 成都分迪药业有限公司 酰胺类化合物及其用途
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023070120A1 (en) * 2021-10-22 2023-04-27 Biotheryx, Inc. Ketoamides for treating malignancy
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
JP2025522795A (ja) * 2022-06-27 2025-07-17 ピン セラピューティクス、インコーポレイテッド カゼインキナーゼ１アルファを分解するための化合物及び方法
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
JP2025531869A (ja) * 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024167423A1 (en) * 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
WO2025067255A1 (zh) * 2023-09-26 2025-04-03 映恩生物制药（苏州）有限公司 哌啶二酮类化合物、其制备方法和用途
WO2026098548A1 (zh) * 2024-11-07 2026-05-15 四川科伦博泰生物医药股份有限公司 蛋白降解剂、其药物组合物及其用途和方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525889A (ja) * 2000-12-27 2004-08-26 セルジーン・コーポレーション イソインドール−イミド化合物、組成物、およびそれらの使用
JP2010539206A (ja) * 2007-09-19 2010-12-16 ４エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
KR20170132934A (ko) * 2016-05-24 2017-12-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20180170948A1 (en) * 2016-12-21 2018-06-21 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
JP2019507114A (ja) * 2016-01-08 2019-03-14 セルジーン コーポレイション 抗増殖化合物、ならびにそれらの薬学的組成物及び使用
CA3063804A1 (en) * 2017-05-22 2019-12-09 Wigen Biomedicine Technology (shanghai) Co., Ltd. A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
JP2021520372A (ja) * 2018-04-26 2021-08-19 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
WO2018169777A1 (en) 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
US10905684B2 (en) 2018-06-13 2021-02-02 Biotheryx, Inc. Aminoamide compounds
WO2020023782A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525889A (ja) * 2000-12-27 2004-08-26 セルジーン・コーポレーション イソインドール−イミド化合物、組成物、およびそれらの使用
JP2010539206A (ja) * 2007-09-19 2010-12-16 ４エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
JP2019507114A (ja) * 2016-01-08 2019-03-14 セルジーン コーポレイション 抗増殖化合物、ならびにそれらの薬学的組成物及び使用
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
KR20170132934A (ko) * 2016-05-24 2017-12-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20180170948A1 (en) * 2016-12-21 2018-06-21 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CA3063804A1 (en) * 2017-05-22 2019-12-09 Wigen Biomedicine Technology (shanghai) Co., Ltd. A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
JP2021520372A (ja) * 2018-04-26 2021-08-19 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体

Also Published As

Publication number Publication date
US20220298172A1 (en) 2022-09-22
MX2021014345A (es) 2022-01-06
KR20220023343A (ko) 2022-03-02
US20200369679A1 (en) 2020-11-26
CA3140078A1 (en) 2020-12-03
WO2020242960A1 (en) 2020-12-03
CA3140078C (en) 2023-11-28
EP3976623A1 (en) 2022-04-06
CN114502543A (zh) 2022-05-13
IL288204A (en) 2022-01-01
ZA202109124B (en) 2023-10-25
TW202110818A (zh) 2021-03-16
AU2020283744A1 (en) 2021-12-09
SG11202112355VA (en) 2021-12-30
EA202192910A1 (ru) 2022-03-18
US11345712B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
US11345712B2 (en) Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications
JP7050879B2 (ja) ピラゾール化合物ならびにこの化合物を作製および使用するための方法
US12060367B2 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20240246954A1 (en) Compositions and methods for inhibiting kras
US9133187B2 (en) Serine/threonine kinase inhibitors
US10059705B2 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
US20240408093A1 (en) Heterobifunctional compounds and their use in treating disease
JP2021527098A (ja) 縮合チオフェン化合物
US20250268925A1 (en) Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted adeninyl-propyloxy phosphonic acid or related compound
TWI716976B (zh) 高活性sting蛋白激動劑
CN115427394A (zh) 用于调节nr2f6的杂环化合物
US20230227470A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023011596A1 (zh) 酰胺类化合物及其应用
CN117157290A (zh) 用于抑制kras的组合物及方法
US11407831B2 (en) Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203